2014

Ascletis Gains Exclusive China Market Rights from Presidio to Clinical Stage
Hepatitis C Virus (HCV) NS5A Inhibitor PPI-668

Hangzhou, China, Research Triangle Park, NC and San Francisco, CA – November 10, 2014 – Ascletis and Presidio announced today that they have entered into an exclusive licensing agreement for Presidio’s clinical stage, HCV NS5A inhibitor PPI-668, also known as ASC16. The agreement provides Ascletis with exclusive rights to develop and commercialize PPI-668 in Greater China. Presidio will retain all rights in the rest of the world. (PDF)

Pharco Pharmaceuticals Licenses Clinical Stage Hepatitis C Virus (HCV)
NS5A Inhibitor PPI-668 from Presidio Pharmaceuticals

Alexandria, Egypt and San Francisco, CA – November 10, 2014 – Pharco and Presidio today announced that they have entered into an exclusive license agreement for Presidio’s HCV NS5A inhibitor PPI-668 for development and commercialization to treat HCV infection in Egypt. This exclusive license includes an opportunity for Pharco to expand its licensed territory to one or more additional countries in the MENA region. (PDF)